Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Virtu Announces Third Quarter 2024 Results
-
Migrant Rights Network: We Have a Consensus: Permanent Residency & Rights, Not Cuts
-
The Great Twine Round-Up Comes to Alberta with $12,000 in total Cash Prizes
-
Pool Corporation Reports Third Quarter Results
-
DTE Energy reports third quarter 2024 accomplishments, earnings and investments in improving energy infrastructure
-
EyePoint Pharmaceuticals Announces First Patient Dosed in Global Phase 3 LUGANO Clinical Trial of DURAVYUTM for the Treatment of Wet Age-Related Macular Degeneration
-
The Simply Good Foods Company Reports Fiscal Fourth Quarter and Full Fiscal Year 2024 Financial Results and Provides Full Fiscal Year 2025 Outlook
-
Ultralife Corporation to Report Third Quarter Results on November 8, 2024
-
Epitopea Closes USD $31 million Pre-Series A Financing
-
BranchOut Food Shareholder Update: Projects $15M Run Rate and Positive Cash Flow for Q1 2025 Amid Surge in New Orders as Peru Factory Opens
-
New York’s RTS awards NFI subsidiary New Flyer order for 44 Xcelsior heavy-duty transit buses
-
Volvo Study Reveals that rising fuel prices and environmental concerns are driving Gen Z to consider plug-in hybrids for their future vehicle choice
-
XORTX Sponsored Study Presented at the American Society of Nephrology – Kidney Week 2024
-
Beasley Broadcast Group, Inc. Appoints Lauren Burrows Coleman as Chief Financial Officer
-
KCA Confirms Commitment to Xali Gold’s El Oro Tailings Project
-
Kymera Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader, for the Treatment of TH2 Immuno-Inflammatory Diseases
-
Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference
-
Psyence Biomed Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care
-
Auron Presents New Preclinical Data for Lead Program AUTX-703 Across Multiple Cancer Types
-
Nasdaq Reports Third Quarter 2024 Results; Fourth Consecutive Quarter of Double-Digit Solutions Revenue Growth
-
Rivian and Patagonia Partner with Sol Systems to Drive Renewable Energy in Stokes County, NC
-
Axogen, Inc. to report third quarter 2024 financial results and host conference call on November 7, 2024
-
iTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 A2A-005 Clinical Trial Data in 2L NSCLC at ESMO Immuno-Oncology Congress
-
Flock Safety Launches First-of-Its-Kind Sideshow Detection Technology to Help Communities Combat Illegal Sideshows
-
VSDHOne Expands to Offer Asynchronous Telehealth Treatments Including Skincare, Hair Loss, and Sexual Health
-
Surge Copper Intersects 412 metres grading 0.40% CuEq including ?54 metres grading 0.53% CuEq at the Berg Deposit
-
American Airlines Reports Third-Quarter 2024 Financial Results
-
ConnectOne Bancorp, Inc. Reports Third Quarter 2024 Results; Declares Common and Preferred Dividends
-
Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate
-
Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference
-
Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology C
-
2024 Fortune Best Workplaces for Women Lead the Way Beyond Fair Pay
-
Tecnoglass Sets Date for Third Quarter 2024 Results
-
Cibus to Report Third Quarter 2024 Financial Results on November 7, 2024 After the Market Close and Host Conference Call
-
VEON’s Jazz Launches FikrFree: An AI-Powered Digital Marketplace to Unlock Affordable Insurance and Healthcare in Pakistan
-
HONKARAKENNE OYJ - MANAGERS’ TRANSACTIONS
-
Avacta Reports Pipeline Advances with Two Novel Programs at the EORTC-NCI-AACR Molecular Targets Symposium in Barcelona
-
Aya Gold & Silver: Q3-2024 Results and Conference Call on November 14
-
Fidelity D & D Bancorp, Inc.: Increases for Ten Consecutive Years with 5% Rise in Fourth Quarter 2024 Dividend
-
Steve Madden Announces Third Quarter 2024 Earnings Release Date
-
Garrett Motion Reports Third Quarter 2024 Financial Results; Updates Full Year 2024 Outlook
-
Jayden Liu’s NeuroAqua: An AI-Driven Aquaponics System of Sustainable Farming Featured in XYZ Media’s ‘Next Generation of Innovators’
-
ADT Reports Third Quarter 2024 Results
-
Visteon Announces Third Quarter 2024 Results
-
Bread Financial Provides Performance Update for September 2024
-
Northrop Grumman Releases Third Quarter 2024 Financial Results
-
Wabash Announces Third Quarter 2024 Results
-
Reliance, Inc. Reports Third Quarter 2024 Financial Results
-
ANI Pharmaceuticals to Present New Data Highlighting Membranous Nephropathy Research at American Society of Nephrology Kidney Week 2024
-
Bread Financial Reports Third Quarter 2024 Results
